RaySearch Laboratories B

RaySearch Laboratories reported preliminary Q2 figures that fell well short of expectations: net sales declined year-on-year with an organic growth of -8% and operating profit dropped sharply. Management attributed the decline to delayed US deals that have not been cancelled but have not yet been realized. Order intake improved, but investors are pricing in short-term sales uncertainty, sending the stock to a 52-week low. Sentiment is likely to remain muted until the full Q2 report is released unless a timeline is provided for converting the deferred orders. » More on de.investing.com

RaySearch reports Q1 2026 EPS of 1.56 SEK vs. expected 1.46 SEK, while net sales fell to 290 million SEK (−20% y/y), missing forecasts of 317 million SEK. The operating margin remained stable at 23% and the stock rose 1.54% in pre-market trading. The revenue decline was partly attributed to currency effects and lower license revenues; management expects EPS of 0.14–0.21 SEK for the coming quarters and anticipates delayed closings in Q2/Q3. » More on de.investing.com

RaySearch reported a 20% revenue decline in Q1 2026 to SEK 290m, missing the SEK 317m forecast. The operating margin remained at 23% (EBIT SEK 68m) despite the revenue drop, while order intake fell 13%. Currency effects and lower license revenues weighed on results, and cash stood at SEK 439m. After the figures, the stock initially fell about 11.1%; management issued EPS forecasts of USD 0.15 for Q2 and USD 0.17 for Q3 2026 and aims to stabilise revenue through higher support income and currency management. » More on de.investing.com